ICANS

Clinical trials for ICANS explained in plain language.

Never miss a new study

Get alerted when new ICANS trials appear

Sign up with your email to follow new studies for ICANS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 1

Blue dye may tame dangerous immune reactions

Symptom relief Recruiting now

This early-stage study tests whether adding methylene blue to standard care can safely reduce cytokine release syndrome (CRS) and neurotoxicity (ICANS) in 18 adults who developed these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue …

Matched conditions: ICANS

Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Symptom relief

Last updated May 13, 2026 16:00 UTC

ICANS

Get alerted when new ICANS trials appear

Blue dye may tame dangerous immune reactions